Mankind Pharma to acquire 70% stake in Belgium biotech ACTx for EUR 48M

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

MANKIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.1%Reaction day

₹2347.60

prior close

₹2349.90

announcement price

After-mkt

timing

Nifty Midcap 150market-0.1%-3.0% vs market

Pharmaceuticals peers, median of 173sector+0.1%-3.2% vs sector

On the reaction day the stock moved 3.0 pts less than Nifty Midcap 150 and 3.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

-0.9

15m

-0.8

30m

-1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.1-0.1-3.0+0.1-3.2

Next day

-4.0-1.2-2.8-1.2-2.8

-2.6-2.6-0.1-3.0+0.3

-3.1-3.3+0.3-3.9+0.8

-5.8-5.3-0.4-5.0-0.7

-1.5-4.3+2.8-3.9+2.4

+6.1-3.2+9.2-0.9+7.0

15d

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Mankind Pharma board approved investing up to EUR 45M more into its wholly owned Netherlands subsidiary (total EUR 50M) to fund acquisition of 70% stake in Armed Cell Therapeutics B.V. (ACTx), a Belgium biotech, for EUR 48M in cash. ACTx develops next-generation CAR-T therapies for cancer, with lead programs in non-Hodgkin lymphoma and small cell lung cancer. Founders include former Galapagos and Johnson & Johnson executives.

Likely market impact

Strategic move into innovation-led biotech and cell therapy space, outside core pharma. Could boost long-term growth narrative; execution and pipeline risks remain.